title: [Refractory neurosarcoidosis and infliximab: a growing experience].
abstract: Neurosarcoidosis is a rare disease that can involve all the nervous system with variable clinical onset and prognosis. The initial therapeutic approach is mainly based on corticosteroids and immunosuppressive agents. Treatment of refractory forms of neurosarcoidosis is not well established and emerging immunomodulating drugs like infliximab have been recently tested. The clinical report of a new case of neurosarcoidosis responding to infliximab is followed by a review of the new therapeutic agents available for the treatment of refractory neurosarcoidosis.
authors.affiliation: Service de Neurologie D, Hôpital Neurologique, CHU de Lyon, 59 Boulevard Pinel, 69677 Bron Cedex, France. thomas.ritzenthaler@chu-lyon.fr
authors.forename: T
authors.initials: T
authors.lastname: Ritzenthaler
authors.forename: V
authors.initials: V
authors.lastname: Gonzalez-Martinez
authors.forename: A
authors.initials: A
authors.lastname: Guegen
authors.forename: C
authors.initials: C
authors.lastname: Tilikete
authors.forename: A
authors.initials: A
authors.lastname: Vighetto
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D008279:Magnetic Resonance Imaging; D009422:Nervous System Diseases / Q000188:drug therapy* / Q000473:pathology; D012507:Sarcoidosis / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab